Share Price and Basic Stock Data
Last Updated: November 28, 2025, 10:12 am
| PEG Ratio | 1.61 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Ambar Protein Industries Ltd operates within the Edible Oils and Solvent Extraction industry. The company has shown a consistent upward trajectory in sales, reporting ₹340 Cr in revenue for the fiscal year ending March 2023, which rose to ₹421 Cr for March 2025, reflecting a strong growth rate. The trailing twelve months (TTM) sales stood at ₹469 Cr, indicating robust demand for its products. Quarterly sales data shows fluctuations, with a peak of ₹127.81 Cr recorded in March 2025 and a dip to ₹68.61 Cr in September 2023. This volatility in quarterly sales can be attributed to seasonal factors and market dynamics. However, the overall trend demonstrates a clear recovery and growth phase, particularly in recent quarters. The company’s ability to maintain sales growth amidst varying expenses, which increased from ₹330 Cr in March 2022 to ₹406 Cr in March 2025, highlights its operational resilience and market positioning.
Profitability and Efficiency Metrics
Ambar Protein Industries has reported a commendable operating profit margin (OPM) of 4% for March 2025, a notable increase from 2% in March 2023. This improvement in profitability is indicative of effective cost management and operational efficiency. The company’s return on equity (ROE) stood at 27.79% for March 2025, showcasing strong returns for its shareholders. Furthermore, the return on capital employed (ROCE) increased significantly to 41.06%, reflecting the company’s efficient use of capital to generate profits. The interest coverage ratio (ICR) of 7.32x indicates that Ambar Protein can comfortably meet its interest obligations, thereby reducing financial risk. However, the operating profit exhibited fluctuations, declining to a low of ₹0.83 Cr in March 2023 before rebounding to ₹16 Cr in March 2025. Such variability necessitates continued monitoring of operational efficiencies and cost structures to ensure sustained profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of Ambar Protein Industries reflects a robust financial position, with a total debt-to-equity ratio of 0.74 as of March 2025, indicating moderate leverage. The absence of long-term debt signifies a strong equity base, allowing the company to maintain financial flexibility. The current ratio of 1.45 suggests that the company is well-positioned to cover its short-term liabilities, enhancing liquidity. Additionally, the book value per share increased from ₹25.48 in March 2021 to ₹60.39 in March 2025, demonstrating substantial growth in shareholder value. The price-to-book value (P/BV) ratio stood at 3.36x, which is slightly above the typical sector range, indicating a premium valuation. However, the company’s cash conversion cycle (CCC) of 34 days in March 2025 shows a need for improvement in operational efficiency, particularly in managing inventory and receivables.
Shareholding Pattern and Investor Confidence
The shareholding structure of Ambar Protein Industries reveals a strong promoter backing, with promoters holding 71.48% of the company as of September 2025. This substantial stake reflects confidence in the company’s long-term growth prospects. The public shareholding has gradually decreased to 28.51%, indicating a consolidation of ownership among existing shareholders. The number of shareholders has also seen an increase, rising to 3,177 by September 2025, which may suggest growing investor interest. However, the lack of foreign institutional investments (FIIs) and domestic institutional investments (DIIs) could indicate limited institutional confidence in the stock, potentially affecting liquidity. The stability in promoter holding reinforces investor trust, but the company must attract institutional investors to enhance its market presence.
Outlook, Risks, and Final Insight
Looking ahead, Ambar Protein Industries is well-positioned for growth, driven by its expanding product portfolio and operational efficiencies. However, the company faces risks, including potential fluctuations in raw material prices and market competition, which could impact margins. Additionally, the variability in quarterly earnings highlights the need for consistent performance to maintain investor confidence. If the company can sustain its profitability and improve its operational metrics, it may attract institutional investments, further solidifying its market position. Conversely, failure to address operational inefficiencies and maintaining strong sales growth could hinder its financial performance. Ultimately, the company’s ability to navigate these challenges will determine its long-term success and shareholder value creation.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Ambar Protein Industries Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| IEL Ltd | 103 Cr. | 7.90 | 10.3/3.87 | 3.37 | 0.00 % | 2.51 % | 1.91 % | 1.00 | |
| Evexia Lifecare Ltd | 315 Cr. | 1.68 | 4.40/1.52 | 221 | 3.02 | 0.00 % | 0.30 % | 0.32 % | 1.00 |
| Diligent Industries Ltd | 64.6 Cr. | 2.71 | 4.90/1.45 | 25.1 | 2.79 | 0.00 % | 7.06 % | 6.09 % | 1.00 |
| CIAN Agro Industries & Infrastructure Ltd | 3,725 Cr. | 1,331 | 3,633/321 | 1,835 | 33.0 | 0.00 % | 8.54 % | 1.06 % | 10.0 |
| BCL Industries Ltd | 1,016 Cr. | 34.4 | 57.8/33.0 | 9.76 | 28.9 | 0.75 % | 13.2 % | 13.0 % | 1.00 |
| Industry Average | 10,481.00 Cr | 167.09 | 152.38 | 33.77 | 0.18% | 14.09% | 12.05% | 4.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 84.38 | 75.77 | 94.92 | 90.00 | 93.22 | 68.61 | 85.72 | 89.51 | 93.04 | 88.95 | 111.82 | 127.81 | 117.27 |
| Expenses | 81.92 | 74.30 | 92.42 | 89.17 | 90.62 | 67.04 | 81.90 | 90.26 | 90.10 | 84.72 | 107.00 | 124.02 | 115.13 |
| Operating Profit | 2.46 | 1.47 | 2.50 | 0.83 | 2.60 | 1.57 | 3.82 | -0.75 | 2.94 | 4.23 | 4.82 | 3.79 | 2.14 |
| OPM % | 2.92% | 1.94% | 2.63% | 0.92% | 2.79% | 2.29% | 4.46% | -0.84% | 3.16% | 4.76% | 4.31% | 2.97% | 1.82% |
| Other Income | 0.11 | 0.13 | 0.12 | 0.14 | 0.12 | 0.12 | 0.12 | 0.31 | 0.22 | 0.22 | 0.19 | 0.20 | 0.19 |
| Interest | 0.62 | 0.66 | 0.65 | 0.60 | 0.64 | 0.63 | 0.69 | 0.50 | 0.56 | 0.56 | 0.57 | 0.58 | 0.53 |
| Depreciation | 0.32 | 0.32 | 0.32 | 0.31 | 0.33 | 0.26 | 0.39 | 0.34 | 0.32 | 0.32 | 0.46 | 0.21 | 0.33 |
| Profit before tax | 1.63 | 0.62 | 1.65 | 0.06 | 1.75 | 0.80 | 2.86 | -1.28 | 2.28 | 3.57 | 3.98 | 3.20 | 1.47 |
| Tax % | 17.79% | 27.42% | 37.58% | 116.67% | 27.43% | 2.50% | 45.10% | -64.84% | 24.56% | 24.65% | 29.15% | 22.19% | 48.98% |
| Net Profit | 1.34 | 0.46 | 1.03 | -0.02 | 1.26 | 0.78 | 1.56 | -0.45 | 1.72 | 2.69 | 2.82 | 2.48 | 0.75 |
| EPS in Rs | 2.33 | 0.80 | 1.79 | -0.03 | 2.19 | 1.36 | 2.71 | -0.78 | 2.99 | 4.68 | 4.90 | 4.31 | 1.30 |
Last Updated: August 19, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Ambar Protein Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 117.27 Cr.. The value appears to be declining and may need further review. It has decreased from 127.81 Cr. (Mar 2025) to 117.27 Cr., marking a decrease of 10.54 Cr..
- For Expenses, as of Jun 2025, the value is 115.13 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 124.02 Cr. (Mar 2025) to 115.13 Cr., marking a decrease of 8.89 Cr..
- For Operating Profit, as of Jun 2025, the value is 2.14 Cr.. The value appears to be declining and may need further review. It has decreased from 3.79 Cr. (Mar 2025) to 2.14 Cr., marking a decrease of 1.65 Cr..
- For OPM %, as of Jun 2025, the value is 1.82%. The value appears to be declining and may need further review. It has decreased from 2.97% (Mar 2025) to 1.82%, marking a decrease of 1.15%.
- For Other Income, as of Jun 2025, the value is 0.19 Cr.. The value appears to be declining and may need further review. It has decreased from 0.20 Cr. (Mar 2025) to 0.19 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Jun 2025, the value is 0.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.58 Cr. (Mar 2025) to 0.53 Cr., marking a decrease of 0.05 Cr..
- For Depreciation, as of Jun 2025, the value is 0.33 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.21 Cr. (Mar 2025) to 0.33 Cr., marking an increase of 0.12 Cr..
- For Profit before tax, as of Jun 2025, the value is 1.47 Cr.. The value appears to be declining and may need further review. It has decreased from 3.20 Cr. (Mar 2025) to 1.47 Cr., marking a decrease of 1.73 Cr..
- For Tax %, as of Jun 2025, the value is 48.98%. The value appears to be increasing, which may not be favorable. It has increased from 22.19% (Mar 2025) to 48.98%, marking an increase of 26.79%.
- For Net Profit, as of Jun 2025, the value is 0.75 Cr.. The value appears to be declining and may need further review. It has decreased from 2.48 Cr. (Mar 2025) to 0.75 Cr., marking a decrease of 1.73 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.30. The value appears to be declining and may need further review. It has decreased from 4.31 (Mar 2025) to 1.30, marking a decrease of 3.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:59 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 157 | 168 | 195 | 206 | 231 | 284 | 313 | 340 | 345 | 336 | 421 | 469 |
| Expenses | 159 | 155 | 167 | 193 | 203 | 227 | 278 | 305 | 330 | 338 | 328 | 406 | 455 |
| Operating Profit | 1 | 2 | 2 | 3 | 3 | 4 | 6 | 8 | 9 | 7 | 7 | 16 | 13 |
| OPM % | 1% | 1% | 1% | 1% | 1% | 2% | 2% | 2% | 3% | 2% | 2% | 4% | 3% |
| Other Income | 0 | 1 | 0 | 1 | 1 | 0 | 0 | -0 | 1 | 0 | 0 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 2 | 2 | 2 |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 2 | 1 | 2 | 3 | 3 | 3 | 4 | 6 | 4 | 4 | 13 | 11 |
| Tax % | 0% | 0% | 36% | 2% | 27% | 28% | 55% | 13% | 25% | 29% | 24% | 26% | |
| Net Profit | 0 | 2 | 1 | 2 | 2 | 2 | 1 | 3 | 4 | 3 | 3 | 10 | 8 |
| EPS in Rs | 0.14 | 2.70 | 1.51 | 4.19 | 3.74 | 3.53 | 2.17 | 6.00 | 7.74 | 4.89 | 5.48 | 16.78 | 13.99 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -50.00% | 100.00% | 0.00% | 0.00% | -50.00% | 200.00% | 33.33% | -25.00% | 0.00% | 233.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 150.00% | -100.00% | 0.00% | -50.00% | 250.00% | -166.67% | -58.33% | 25.00% | 233.33% |
Ambar Protein Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| TTM: | 32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 20% |
| 5 Years: | 50% |
| 3 Years: | 29% |
| TTM: | 142% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -2% |
| 1 Year: | 127% |
| Return on Equity | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 23% |
| 3 Years: | 21% |
| Last Year: | 32% |
Last Updated: September 5, 2025, 2:16 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 3 | 2 | 3 | 8 | 3 | 2 | 3 | 4 | 10 | 15 | 15 | 18 |
| Inventory Days | 11 | 12 | 18 | 19 | 16 | 37 | 20 | 22 | 32 | 23 | 24 | 20 |
| Days Payable | 13 | 10 | 11 | 9 | 6 | 10 | 3 | 5 | 9 | 7 | 8 | 3 |
| Cash Conversion Cycle | 1 | 4 | 10 | 18 | 13 | 29 | 19 | 21 | 33 | 30 | 31 | 34 |
| Working Capital Days | -8 | -8 | -4 | -1 | -4 | -9 | -8 | -2 | 3 | 4 | 6 | 12 |
| ROCE % | 8% | 28% | 18% | 22% | 17% | 13% | 15% | 18% | 18% | 13% | 13% | 28% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Diluted EPS (Rs.) | 16.78 | 5.47 | 4.92 | 7.74 | 6.00 |
| Cash EPS (Rs.) | 19.06 | 7.75 | 7.11 | 9.97 | 8.09 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.39 | 43.60 | 38.13 | 33.21 | 25.48 |
| Revenue From Operations / Share (Rs.) | 733.26 | 586.19 | 600.13 | 590.87 | 544.87 |
| PBDIT / Share (Rs.) | 28.89 | 13.72 | 13.50 | 17.18 | 13.61 |
| PBIT / Share (Rs.) | 26.61 | 11.43 | 11.29 | 14.95 | 11.52 |
| PBT / Share (Rs.) | 22.66 | 7.16 | 6.88 | 10.27 | 6.92 |
| Net Profit / Share (Rs.) | 16.78 | 5.47 | 4.89 | 7.74 | 6.00 |
| PBDIT Margin (%) | 3.93 | 2.34 | 2.25 | 2.90 | 2.49 |
| PBIT Margin (%) | 3.62 | 1.95 | 1.88 | 2.53 | 2.11 |
| PBT Margin (%) | 3.09 | 1.22 | 1.14 | 1.73 | 1.27 |
| Net Profit Margin (%) | 2.28 | 0.93 | 0.81 | 1.30 | 1.10 |
| Return on Networth / Equity (%) | 27.79 | 12.54 | 12.83 | 23.30 | 23.54 |
| Return on Capital Employeed (%) | 41.06 | 23.61 | 24.19 | 34.46 | 30.62 |
| Return On Assets (%) | 13.68 | 5.12 | 4.51 | 6.93 | 6.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.01 | 0.07 | 0.14 | 0.24 |
| Total Debt / Equity (X) | 0.74 | 1.02 | 1.34 | 1.72 | 1.86 |
| Asset Turnover Ratio (%) | 6.39 | 5.45 | 5.46 | 5.94 | 6.29 |
| Current Ratio (X) | 1.45 | 1.21 | 1.19 | 1.11 | 1.00 |
| Quick Ratio (X) | 0.83 | 0.61 | 0.63 | 0.42 | 0.39 |
| Inventory Turnover Ratio (X) | 20.84 | 16.08 | 13.93 | 14.65 | 18.92 |
| Interest Coverage Ratio (X) | 7.32 | 3.21 | 3.07 | 3.67 | 2.96 |
| Interest Coverage Ratio (Post Tax) (X) | 5.26 | 2.28 | 2.11 | 2.65 | 2.30 |
| Enterprise Value (Cr.) | 141.53 | 108.01 | 151.38 | 48.68 | 29.74 |
| EV / Net Operating Revenue (X) | 0.33 | 0.32 | 0.43 | 0.14 | 0.09 |
| EV / EBITDA (X) | 8.52 | 13.69 | 19.50 | 4.93 | 3.80 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| Price / BV (X) | 3.36 | 3.34 | 5.62 | 0.89 | 0.27 |
| Price / Net Operating Revenue (X) | 0.27 | 0.24 | 0.35 | 0.05 | 0.01 |
| EarningsYield | 0.08 | 0.03 | 0.02 | 0.26 | 0.85 |
After reviewing the key financial ratios for Ambar Protein Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Diluted EPS (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.06. This value is within the healthy range. It has increased from 7.75 (Mar 24) to 19.06, marking an increase of 11.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.39. It has increased from 43.60 (Mar 24) to 60.39, marking an increase of 16.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 733.26. It has increased from 586.19 (Mar 24) to 733.26, marking an increase of 147.07.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.89. This value is within the healthy range. It has increased from 13.72 (Mar 24) to 28.89, marking an increase of 15.17.
- For PBIT / Share (Rs.), as of Mar 25, the value is 26.61. This value is within the healthy range. It has increased from 11.43 (Mar 24) to 26.61, marking an increase of 15.18.
- For PBT / Share (Rs.), as of Mar 25, the value is 22.66. This value is within the healthy range. It has increased from 7.16 (Mar 24) to 22.66, marking an increase of 15.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 16.78. This value is within the healthy range. It has increased from 5.47 (Mar 24) to 16.78, marking an increase of 11.31.
- For PBDIT Margin (%), as of Mar 25, the value is 3.93. This value is below the healthy minimum of 10. It has increased from 2.34 (Mar 24) to 3.93, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 3.62. This value is below the healthy minimum of 10. It has increased from 1.95 (Mar 24) to 3.62, marking an increase of 1.67.
- For PBT Margin (%), as of Mar 25, the value is 3.09. This value is below the healthy minimum of 10. It has increased from 1.22 (Mar 24) to 3.09, marking an increase of 1.87.
- For Net Profit Margin (%), as of Mar 25, the value is 2.28. This value is below the healthy minimum of 5. It has increased from 0.93 (Mar 24) to 2.28, marking an increase of 1.35.
- For Return on Networth / Equity (%), as of Mar 25, the value is 27.79. This value is within the healthy range. It has increased from 12.54 (Mar 24) to 27.79, marking an increase of 15.25.
- For Return on Capital Employeed (%), as of Mar 25, the value is 41.06. This value is within the healthy range. It has increased from 23.61 (Mar 24) to 41.06, marking an increase of 17.45.
- For Return On Assets (%), as of Mar 25, the value is 13.68. This value is within the healthy range. It has increased from 5.12 (Mar 24) to 13.68, marking an increase of 8.56.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.74. This value is within the healthy range. It has decreased from 1.02 (Mar 24) to 0.74, marking a decrease of 0.28.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 6.39. It has increased from 5.45 (Mar 24) to 6.39, marking an increase of 0.94.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. It has increased from 1.21 (Mar 24) to 1.45, marking an increase of 0.24.
- For Quick Ratio (X), as of Mar 25, the value is 0.83. This value is below the healthy minimum of 1. It has increased from 0.61 (Mar 24) to 0.83, marking an increase of 0.22.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 20.84. This value exceeds the healthy maximum of 8. It has increased from 16.08 (Mar 24) to 20.84, marking an increase of 4.76.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.32. This value is within the healthy range. It has increased from 3.21 (Mar 24) to 7.32, marking an increase of 4.11.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 5.26. This value is within the healthy range. It has increased from 2.28 (Mar 24) to 5.26, marking an increase of 2.98.
- For Enterprise Value (Cr.), as of Mar 25, the value is 141.53. It has increased from 108.01 (Mar 24) to 141.53, marking an increase of 33.52.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 1. It has increased from 0.32 (Mar 24) to 0.33, marking an increase of 0.01.
- For EV / EBITDA (X), as of Mar 25, the value is 8.52. This value is within the healthy range. It has decreased from 13.69 (Mar 24) to 8.52, marking a decrease of 5.17.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For Price / BV (X), as of Mar 25, the value is 3.36. This value exceeds the healthy maximum of 3. It has increased from 3.34 (Mar 24) to 3.36, marking an increase of 0.02.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.24 (Mar 24) to 0.27, marking an increase of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.08. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Ambar Protein Industries Ltd:
- Net Profit Margin: 2.28%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 41.06% (Industry Average ROCE: 14.09%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 27.79% (Industry Average ROE: 12.05%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 5.26
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.83
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 20.2 (Industry average Stock P/E: 152.38)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.74
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.28%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Edible Oils & Solvent Extraction | Block No. 351p2, 353p2 and 358, Panchratna Estate, Ahmedabad District Gujarat 382213 | ambarinv@gmail.com http://www.ambarprotein.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pradeep C Khetani | Managing Director |
| Mr. Jayprakash J Vachhani | Whole Time Director |
| Mr. Shirishkumar D Patel | Director |
| Mr. Bharatbhai D Patel | Director |
| Mr. Dashrathbhai A Patel | Director |
| Mrs. Shobhanaben J Vachhani | Director |
| Mr. Gangaram Bhanjibhai Patel | Independent Director |
| Mr. Yogen Pranjivandas Patel | Independent Director |
| Mr. Narottam Chaturdas Tanna | Independent Director |